This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Find out more here.

eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
New eMC coming June 2013...

Boehringer Ingelheim Limited Consumer Healthcare

Ellesfield Avenue, Bracknell, Berkshire, RG12 8YS
Telephone: +44 (0)1344 424 600
Fax: +44 (0)1344 741 399
WWW: http://www.boehringer-ingelheim.co.uk
Medical Information Direct Line: +44 (0)1344 742 579
Medical Information e-mail: medinfo@bra.boehringer-ingelheim.com
Customer Care direct line: +44 (0)1344 741 186
Medical Information Fax: +44 (0)1344 741 298

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 20/03/2014
SPC Pharmaton Vitality Capsules


Go to top of the page
1. Name of the medicinal product

Pharmaton Vitality Capsules


Go to top of the page
2. Qualitative and quantitative composition

Each capsule contains:

Active Ingredients

 

Declaration per capsule

G115 Panax Ginseng extract

 

40.0

mg

[dry extract ethanolic 40%: 1.3 – 3:1]

 

 

 

Vitamin A Palmitate

(Vit.A)

2667

IU

Colecalciferol

(Vit.D3)

200

IU

D,L-α-Tocopherol acetate

(Vit.E)

10

mg

Thiamine mononitrate

(Vit.B1)

1.4

mg

Riboflavin

(Vit.B2)

1.6

mg

Pyridoxine hydrochloride

(Vit.B6)

2.0

mg

Cyanocobalamine

(Vit.B12)

1.0

mcg

Biotin

 

150.0

mcg

Nicotinamide

 

18.0

mg

Ascorbic acid

 

60.0

mg

Folic acid

 

0.1

mg

Copper(II) sulfate dried

(Cu:2.0 mg)

5.6

mg

Sodium selenite, dried

(Se:50.0 mcg)

111.0

mcg

Magnesium sulfate, dried

(Mg:10.0 mg)

71.0

mg

Iron(II) sulfate, dried

(Fe:10.0 mg)

33.0

mg

Zinc sulfate, monohydrate

(Zn:1.0 mg)

2.75

mg

Dibasic calcium phosphate, anhydrous

(Ca:100.0 mg)

340.0

mg

Lecithin (containing choline, inositol, linoleic acid, linolenic acid)

 

100.0

mg


Go to top of the page
3. Pharmaceutical form

Soft gelatin capsules for oral use.


Go to top of the page
4. Clinical particulars

Go to top of the page
4.1 Therapeutic indications

Pharmaton Vitality Capsules contain vitamins, minerals and standardised Ginseng Extract G115 in amounts which suit the body's daily requirements.

The capsules are indicated for relief of temporary periods of: States of exhaustion (e.g. caused by stress), tiredness, feeling of weakness, vitality deficiency.

Prevention and treatment of symptoms caused by ill-balanced or deficient nutrition.


Go to top of the page
4.2 Posology and method of administration

For situations of short term tiredness and exhaustion, Pharmaton Vitality Capsules are recommended for 4 weeks. If symptoms have not shown any improvement after 4 weeks, consult a doctor. Pharmaton Vitality Capsules may be taken for periods of up to 12 weeks. For longer term use consult a doctor.

Adults:

The recommended daily dosage is one capsule per day .

The capsule should preferably be taken in the morning with food.

Children:

Not recommended for use in children.

Elderly:

There are no special dosage recommendations for the elderly.


Go to top of the page
4.3 Contraindications

Pharmaton Vitality Capsules are contraindicated in patients with disturbances of calcium metabolism (e.g. hypercalcaemia and hypercalciuria), hypervitaminosis A or D, renal insufficiency, concomitant retinoid (e.g. for acne) or vitamin D therapy, haemochromatosis, iron overload syndrome and in patients with known hypersensitivity to any of the ingredients in the product.

Pharmaton Vitality Capsules contain arachis oil (peanut oil) and should not be taken by patients known to be allergic to peanut. As there is a possible relationship between allergy to peanut and allergy to soya, patients with soya allergy should also avoid Pharmaton Vitality Capsules.

In case of rare hereditary conditions that may be incompatible with an excipient of the product (please refer to “Special warnings and precautions for use”), the use of the product is contraindicated.


Go to top of the page
4.4 Special warnings and precautions for use

Patients with a family history of haemochromatosis should seek medical advice before taking Pharmaton Vitality Capsules.

An allowance should be made for vitamins or minerals obtained from other sources.

In states of exhaustion (e.g. caused by stress), clinical trials have shown that improvement starts usually within 4 weeks of treatment. If symptoms have not shown any improvement during that time, or you are concerned, please consult your doctor.

The label will state “Important warning: Contains iron. Keep out of the reach and sight of children, as overdose may be fatal”. This will appear on the labelling within a rectangle in which there is no other information.

Patients taking warfarin (or other coumarin anticoagulants) should have increased monitoring of their INR levels when starting or stopping treatment with ginseng containing products.

Each capsule contains a small amount of lactose (26 mg). Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

In case of concomitant intake of ginseng preparations and anticoagulants, the effect of oral blood thinning medication (e.g. warfarin) may potentially be reduced. Patients on blood thinning medications should seek medical advice before starting this product.

Interactions of iron with tetracycline antibiotics (tetracycline, doxycline, minocycline) and vitamin B6 and levodopa are known. Patients on any of these medications should seek medical advice before starting this product.


Go to top of the page
4.6 Fertility, pregnancy and lactation

Pregnancy and lactation

Reproduction studies with animals using the standardized Panax ginseng extract G115 Pharmaton showed no teratogenic effects. However, controlled studies with pregnant women are not available.

Controlled studies with women using multivitamin-mineral preparations at the usual dosage during the course of the first trimester resulted in no fetal risks. There are no signs indicating a risk if this type of preparation is taken during the second and third trimesters, and the probability of injuring the fetus appears to be very low.

Large doses of vitamin A (10,000 IU per day) have been found to be teratogenic if administered during the first trimester of pregnancy. Vitamin D given during the last trimester of pregnancy may cause hypercalcaemia in infants. As with many other medicines an assessment of benefits versus risks should be made before this product is administered during this period.

Pharmaton Vitality Capsules should not be taken during pregnancy or lactation.

Fertility

No studies on the effect on human fertility have been conducted with Pharmaton Vitality Capsules.

Reproduction studies with animals using the standardized Panax ginseng extract G115 Pharmaton showed no adverse effects on fertility.


Go to top of the page
4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed.


Go to top of the page
4.8 Undesirable effects

Adverse events have been ranked under headings of frequency using the following convention:

Very common (≥ 1/10); common (≥ 1/100, < 1/10); uncommon (≥ 1/1000, <1/100); rare (≥ 1/10000, <1/1000); very rare (<1/10000); not known – cannot be estimated from the available data.

Immune system disorders:

Not known: hypersensitivity

Nervous system disorders:

Common: headache

Not known: dizziness

Gastro-intestinal disorders:

Common: nausea, vomiting

Uncommon: diarrhoea

Not known: abdominal pain

Skin and subcutaneous tissue disorders:

Not known: rash, pruritus

Psychiatric disorders

Not known: insomnia

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit / risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.


Go to top of the page
4.9 Overdose

Nervousness may occur following an overdose of the product.

The toxicity of the product in large overdoses is caused by the toxicity of the liposoluble vitamins A and D. A safe dose for both vitamins is considered to be 5-10 x RDA (each capsule contains the EU %RDA for vitamins A and D).

Prolonged supply of larger amounts (40-55 x RDA for Vitamin A; 10-25 x RDA for Vitamin D) can cause symptoms of chronic toxicity. Acute toxic symptoms are only seen at even higher doses.

Iron: Severe acute toxicity in man has been reported from doses of iron ranging from 12-1500 x RDA (each capsule contains the UK %RDA for iron). Most incidents of acute iron toxicity have resulted from accidental oral ingestion of iron pills by children. Longer-term doses of iron up to 6-7 x RDA have been reported to have no toxic effect.

Symptoms: Initial symptoms include nausea, vomiting, diarrhoea, abdominal pain, haematemesis, rectal bleeding, lethargy and circulatory collapse. Hyperglycaemia and metabolic acidosis may also occur.

Treatment: To minimise or prevent further absorption of the medication, as follows:

Induce vomiting e.g. by administration of an emetic.

Gastric lavage with desferrioxamine solution (2g/l). Then desferrioxamine (5 - 10g in 50-100ml water) should be introduced into the stomach to be retained.

Severe poisoning: Shock and/or coma with high iron levels (serum iron >90µmol/l in children, >142µmol/l in adults); immediate supportive measures plus i.v. infusion of desferrioxamine should be instituted.

Less severe poisoning: i.m. desferrioxamine is recommended (1g 4-6 hourly in children; 50mg/kg up to a maximum dose of 4g in adults).


Go to top of the page
5. Pharmacological properties

Go to top of the page
5.1 Pharmacodynamic properties

Pharmaton Vitality Capsules exert a stimulant effect at physical and psychological levels through the combined action of various substances on the basic metabolic processes.

The standardised ginseng extract G115 raises the general level of cellular activity, which is expressed by a pronounced increase in the physical and mental capacity.

In animal experiments, it caused a reduction of lactic acid concentration in muscles during exercise. An increase in the dopamine and noradrenaline content and a reduction in the serotonin content in the brain stem could be observed.

Vitamins, minerals and trace elements correct and prevent impairment of the cell metabolism in situations with increased demands. Low supply of vitamins, minerals, and trace elements may cause disturbances, such as debility, tiredness, decrease in vitality, reduced force of resistance, and decelerated convalescence. The composition and dosages of the preparation were chosen according to the European RDA-requirements for food supplements.

Choline, inositol, linoleic acid and linolenic acid, in the form of lecithin, improve energy output and lipid metabolism.


Go to top of the page
5.2 Pharmacokinetic properties

Pharmacokinetic studies of Pharmaton Vitality Capsules have not been carried out, because of the complex composition of the product and the small quantities of the active ingredients contained. Moreover, these substances are well known.

Pharmacokinetic studies of the standardised ginseng extract G115 are not possible, because it is a complex extract. In the ginseng root more than 200 substances have been identified to date. Pharmacokinetic studies of individual purified ginsenosides have been carried out in various animal species:

Using radioactively labelled (14C) Ginsenoside Rgl, originated from the standardized Panax ginseng extract G115 Pharmaton, a bioavailability of 30% was determined in mice.

With intraperitoneal application, depending on the tested animal species and the Ginsenoside type, a half-life of between 27 minutes and 14.5 hours was measured.


Go to top of the page
5.3 Preclinical safety data

Acute toxicity

The oral LD50 of the standardized Panax ginseng extract G115 Pharmaton is more than 5 g/kg of body weight in the mouse and the rat, and more than 2 g/kg in the mini-pig.

Reproduction toxicity

The effect of standardized Panax ginseng extract G115 Pharmaton on reproductive performance was studied in two generations of Sprague-Dawley rats. Animals of both sexes were fed either control diet or diet supplemented with the standardized Panax ginseng extract G115 Pharmaton at dose levels of 1.5, 5 or 15 mg/kg body weight/day. Parameters of reproduction and lactation in the treated groups were comparable to those of the controls for two generations of dams and pups. No treatment-related effects were seen in weekly body weights and food consumption, haematological and blood chemistry parameters, and ophthalmic, macroscopic and histopathological examinations.

Fetal toxicity

The standardized Panax ginseng extract G115 Pharmaton, administered to pregnant Wistar rats and pregnant New Zealand rabbits, caused no abnormality in the foetal development.

The rats were treated with 40 mg/kg/day from the 1st to the 15th day after mating.

The rabbits were treated with 20 mg/kg/day from the 7th to the 16th day after mating.

The fetuses were removed by caesarean section on the 21st day in the rats and on the 27th day in the rabbits.


Go to top of the page
6. Pharmaceutical particulars

Go to top of the page
6.1 List of excipients

Capsule:

Rapeseed oil, refined

Hard fat

Ethyl vanillin

Arachis oil (peanut oil)

Triglycerides, medium chain

Gelatin

Lactose monohydrate

Silica, colloidal anhydrous

Capsule shell:

Gelatin

Glycerol 85%

Iron oxide red (E172)

Iron oxide black (E172)


Go to top of the page
6.2 Incompatibilities

None stated.


Go to top of the page
6.3 Shelf life

Glass bottle packs

3 years

Blister packs

2 years


Go to top of the page
6.4 Special precautions for storage

Do not store above 25°C. Keep the container tightly closed.


Go to top of the page
6.5 Nature and contents of container

Brown glass bottles (hydrolytical class III, Ph.Eur) with pilfer proof aluminium caps (with rubber inserts) containing either 30, 40, 60, 90 or 100 capsules. Or Aluminium foil/polyvinylchloride/polyvinylidenchloride blister packs of 4, 30, 40, 60, 90 and 100 capsules.

Current Marketed Packs

Brown glass bottles (hydrolytical class m, Ph.Eur) with pilfer proof aluminium caps (with rubber inserts) containing either 30, 60, or 100 capsules.


Go to top of the page
6.6 Special precautions for disposal and other handling

None stated.


Go to top of the page
7. Marketing authorisation holder

Boehringer Ingelheim Limited (Self Medication Division)

Trading as Pharmaton Natural Health Products

Ellesfield Avenue

Bracknell

Berkshire

RG12 8YS


Go to top of the page
8. Marketing authorisation number(s)

PL 00015/0250


Go to top of the page
9. Date of first authorisation/renewal of the authorisation

03/12/2008


Go to top of the page
10. Date of revision of the text

February 2014



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/325/SPC/


Active Ingredients/Generics